Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERSEUS trial in initially resectable colorectal liver metastases
jRCTs031230683Recruiting
- Sponsor
- Japan Surgical Society
- Start
- Sep 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of oxaliplatin, fluorouracil, capecitabine, tegafur + uracil and folinic acid in colorectal cancer liver metastasis (CRLM) (2 arms), sponsored by Japan Surgical Society. Primary endpoint: 3-year progression-free survival. Started Sep 2024; status: recruiting.
02
Drugs
oxaliplatinfluorouracilcapecitabinetegafur + uracilfolinic acid
03
Conditions
colorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on jRCTs031230683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230683.